Jul 31 |
ALX Oncology reports Phase 2 data for gastric cancer drug evorpacept
|
Jul 31 |
ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer
|
Jul 31 |
ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
|
Jul 9 |
IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data
|
Jul 9 |
Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag
|
Jul 8 |
Dianthus (DNTH) Gains 18% in the Past Month: Here's Why
|
Jul 5 |
Roche (RHHBY) Receives FDA Nod for Vabysmo Prefilled Syringe
|
Jul 4 |
Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals
|
Jul 3 |
Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates
|
Jul 3 |
Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study
|